Company Snapshot Home > Equity > Corporate Information > Company Snapshot
|
|
| Stock Price Details |
|
Chart |
|
|
Last Price (RS)
|
356.40
|
|
Change (%)
|
1.85 (0.52%)
|
|
Best Buy (RS)
|
0(x0)
|
|
Best Sell (RS)
|
0(x0)
|
|
Today's Range (RS)
|
353.10
-
364.65
|
|
52-Week Range (RS)
|
225.75
-
479.45
|
|
Beta (1 Year)
|
1.76
|
|
|
|
|
|
| Index Details |
| BSE HC, BSE SmallCap |
| News |
|
Corporate Details |
| Gujarat Themis Biosyn standalone net profit declines 3.93% in the December 2025 quarter |
| Gujarat Themis Biosyn to conduct board meeting |
|
|
|
| Incoporation Year : 1981 |
| Chairman : Dinesh S Patel |
| Ownership Group : Themis |
| Sector : MAN |
| Industry : Pharmaceuticals - Indian - Bulk Drugs |
| Registered Office |
Gujarat Themis Biosyn Ltd 69/C GIDC Industrial Estate, Valsad Dist, VAPI, Gujarat-396195 |
Phone:91-260-2430027 Fax:91-260-2400639 |
| E-Mail : gtblmumbai@gtbl.in; admin@gtbl.co.in |
| URL : http://www.gtbl.in |
|
| Investor Returns |
|
| |
Date |
Price |
Returns (%) |
| 1Week |
13-May-2026 |
377.50 |
-5.59 |
| 1Month |
20-Apr-2026 |
334.15 |
6.66 |
| 3Month |
20-Feb-2026 |
335.10 |
6.36 |
| 6Month |
20-Nov-2025 |
422.85 |
-15.71 |
| 1Year |
20-May-2025 |
325.90 |
9.36 |
|
|
|
| Mutual Funds Holding |
|
| Scheme Name |
% Holding |
Market Value (Rs Cr.) |
| Quant Manufacturing Fund |
5.41 |
36.21 |
| Quant Value Fund |
0.53 |
9.38 |
| Motilal Oswal BSE Healthcare ETF |
0.08 |
0.03 |
| Bandhan BSE Healthcare Index Fund |
0.08 |
0.01 |
|
|
|
| Groups : Pharmaceuticals - Indian - Bulk Drugs |
|
| Company |
Last Price |
Change (%) |
52Week High |
52Week Low |
Market Cap (Rs Cr.) |
| Divis Laboratories Ltd |
6,893.20 |
-0.28 |
7,077.70 |
5,637.50 |
182,992.80 |
| Acutaas Chemicals Ltd |
2,885.50 |
0.01 |
2,907.80 |
1,059.05 |
23,623.91 |
| Neuland Laboratories Ltd |
16,626.50 |
-0.88 |
19,748.40 |
11,022.40 |
21,331.61 |
| Jubilant Pharmova Ltd |
1,013.15 |
0.18 |
1,250.00 |
783.75 |
16,139.48 |
| Dishman Pharmaceuticals and Chemicals Ltd(Merged) |
301.05 |
0.00 |
0.00 |
0.00 |
4,858.77 |
|
|
|
|